Loading…
Edwards Lifesciences has signed an agreement to acquire JenaValve Technology, a pioneer in transcatheter treatment of aortic regurgitation. JenaValve is a portfolio company of Andera Partners.
JenaValve Technology announced a strategic investment and exclusive technology licensing agreement with Peijia Medical Limited, granting Peijia exclusive rights to develop and commercialize JenaValve's Trilogy TAVR systems in Greater China, in exchange for cash, equity, and milestone payments.